KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Gross Margin (2020 - 2025)

Vir Biotechnology's Gross Margin history spans 6 years, with the latest figure at 99.09% for Q2 2025.

  • On a quarterly basis, Gross Margin rose 78.0% to 99.09% in Q2 2025 year-over-year; TTM through Jun 2025 was 96.08%, a 264.0% decrease, with the full-year FY2025 number at 99.96%, up 110.0% from a year prior.
  • Gross Margin hit 99.09% in Q2 2025 for Vir Biotechnology, down from 100.0% in the prior quarter.
  • Over the last five years, Gross Margin for VIR hit a ceiling of 100.0% in Q1 2021 and a floor of 31.28% in Q2 2022.
  • Historically, Gross Margin has averaged 92.81% across 5 years, with a median of 97.44% in 2024.
  • Biggest five-year swings in Gross Margin: crashed -6804bps in 2022 and later soared 6814bps in 2023.
  • Tracing VIR's Gross Margin over 5 years: stood at 93.0% in 2021, then dropped by -6bps to 87.86% in 2022, then increased by 8bps to 95.25% in 2023, then decreased by -1bps to 94.47% in 2024, then increased by 5bps to 99.09% in 2025.
  • Business Quant data shows Gross Margin for VIR at 99.09% in Q2 2025, 100.0% in Q1 2025, and 94.47% in Q4 2024.